1. Temozolomide-induced hypermutation is associated with high-grade transformation, distant recurrence, and reduced survival after transformation in initially low-grade IDH-mutant diffuse gliomas
- Author
-
Serah Choi, Joanna J. Phillips, Joseph F. Costello, Stephanie Hilz, Nicholas Butowski, Jennie Taylor, Anny Shai, Yao Yu, Daphne A. Haas-Kogan, Susan M. Chang, Jennifer Clarke, Javier Villanueva-Meyer, Nancy Ann Oberheim Bush, Mitchel S. Berger, Matthew R. Grimmer, David A. Solomon, Chibo Hong, Tali Mazor, Mike McDermott, and Annette M. Molinaro
- Subjects
Cancer Research ,Temozolomide ,business.industry ,Distant recurrence ,Mutant ,Somatic hypermutation ,03 medical and health sciences ,Transformation (genetics) ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,medicine ,Cancer research ,business ,030215 immunology ,medicine.drug - Abstract
2506 Background: Temozolomide, a commonly used alkylating agent to treat gliomas, can induce somatic hypermutation. The prevalence and clinical implications of this phenomenon are not well characterized. Methods: We used targeted and whole exome sequencing from a cohort of 82 patients with recurrent IDH-mutant low grade gliomas undergoing re-operation to evaluate the prevalence as well as the clinical implications of hypermutation. Results: Hypermutation was identified at transformation in 57% of recurrent gliomas exposed to Temozolomide, 94% of which were transformed to higher WHO grades. All patients who developed hypermutation were exposed to Temozolomide. Hypermutation was associated with transformation to higher WHO grade (OR 12.0 95% CI 2.5 – 115.5, p = 0.002) and shorter survival after transformation (HR 2.1, 95% CI 1.1-4.0, p = 0.018) compared with non-hypermutated transformed tumors, controlling for grade, molecular subtype, age, and prior radiotherapy. Patients with transformation to glioblastoma had poor survival regardless of hypermutation (p = 0.78). Hypermutated tumors were associated with development of discontiguous disease at a significantly higher frequency (p = 0.003), including four cases with spinal dissemination. Conclusions: TMZ-induced hypermutation is associated with high grade transformation, unique patterns of dissemination and shortened survival after transformation. Next generation sequencing should be considered in this patient population. These data have important implications for the management of newly diagnosed and recurrent IDH-mutant low grade gliomas.
- Published
- 2020